Elutia to Report Second Quarter 2026 Financial Results on Thursday, August 13, 2026
Rhea-AI Summary
Elutia (Nasdaq: ELUT) will release its second quarter 2026 financial results after market close on Thursday, August 13, 2026. Management will host a conference call and webcast at 5:00 p.m. Eastern / 2:00 p.m. Pacific, accessible via online registration and through the Investors section of Elutia’s website.
Positive
- None.
Negative
- None.
Key Figures
Previous Earnings date Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 30 | earnings date | Neutral | -1.0% | Scheduled first-quarter 2026 results release and management conference call |
| Feb 25 | earnings date | Neutral | +5.5% | Scheduled fourth-quarter 2025 results release and management conference call |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Comparable earnings-date announcements produced mixed reactions, ranging from -0.98% to 5.5%.
AI-generated analysis. How Rhea-AI works. Not financial advice.
GAITHERSBURG, Md., July 31, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its second quarter 2026 financial results after market close on Thursday, August 13, 2026. Members of the Company’s management team will host a conference call and webcast starting at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time on the same day.
The conference call can be accessed using the following information:
Webcast: Click here
Dial-In: Click here
To receive the dial-in number, as well as your personalized PIN, you must register at the above link. Once registered, you will also have the option to have the system dial-out to you once the conference call begins. If you forget your PIN prior to the conference call, you can simply re-register.
Please log in approximately 10 minutes prior to the scheduled start time. A live and archived webcast of the event will be available on the “Investors” section of the Elutia website at http://investors.elutia.com/.
About Elutia
Elutia develops and commercializes drug-eluting biomatrix products to improve compatibility between medical devices and the patients who need them. With a growing population in need of implantable technologies, Elutia’s mission is humanizing medicine so patients can thrive without compromise. For more information, visit www.Elutia.com.
Investors:
Elutia Investor Relations
ir@elutia.com